JBI-2174 / Jubilant Pharmova - LARVOL DELTA

Novel, brain penetrant small molecule inhibitor of PD-L1 for targeting glioblastoma and brain metastasis (SITC 2022) - "JBI-2174 showed comparable or better efficacy to the anti-PD-L1 antibody Atezolizumab in hPD-L1/MC38 syngeneic and brain orthotopic models by oral administration with a concomitant increase in tumor infiltrating lymphocytes. Conclusions Oral administration and brain exposure of these small molecule PD-L1 inhibitors provides an attractive option to be used in the treatment of glioblastoma and other solid tumors with brain metastasis. IND enabling studies are being initiated for this molecule to initiate clinical trials in humans."

Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor

Novel, brain penetrant small molecule inhibitor of PD-L1 for targeting glioblastoma and brain metastasis (AACR-NCI-EORTC 2022) - "JBI-2174 showed comparable efficacy to the anti-PD-L1 antibody Atezolizumab in hPD-L1/MC38 syngeneic and orthotopic models by oral administration. Oral administration and brain exposure of JBI-2174 provides an attractive option to be used in the treatment of glioblastoma and other solid tumors with brain metastasis. IND-enabling studies are being initiated for this compound. No"

Brain Cancer • Glioblastoma • Oncology • Solid Tumor • IFNG

Novel, small molecule inhibitors of PD-1/PD-L1 pathway. (ASCO 2022) - "In the in vivo efficacy studies, JBI-2174 showed comparable efficacy to the anti-PD-L1 antibody or Atezolizumab in syngeneic (4T1, CT-26) and in partially humanized models (MC-38/hPD-L1). The oral bioavailability and brain exposure of this molecule will make it attractive for cancers with unmet medical needs such as GBM and brain metastasis. IND enabling studies are being initiated for this compound."

IO biomarker • Brain Cancer • Glioblastoma • Glioma • Oncology • Solid Tumor

Jubilant Therapeutics Inc. Reports Development of Orally Available and Brain Penetrant Small Molecule Inhibitors of PD-L1 at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting (PRNewswire) - "Jubilant Therapeutics...announced data to be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. The data report on the pharmacokinetic and in vitro and in vivo anti-cancer properties of JBI-2174, the Company's lead oral, brain penetrant PD-L1 inhibitor, which is in IND-enabling studies for the treatment for solid tumors....The Company's lead anti-PD-L1 candidate, JBI-2174, demonstrated strong affinity for PD-L1 with an IC50 of approximately 1 nM....In multiple animal models where tumor cells were injected in the brain, JBI-2174 demonstrated sustained brain exposure, efficacy equivalent to an anti-PD-L1 antibody and increased survival compared to control."

PK/PD data • Preclinical • Oncology • Solid Tumor